Skip navigation.

The Capital Fund News

05 APR 2011

PolyTherics and Critical Pharmaceuticals enter drug development collaboration with funding from the Technology Strategy Board

Critical Pharmaceuticals, an emerging biotechnology company and PolyTherics Limited ("PolyTherics"), innovators in precision improvement of proteins and peptides, announced a collaboration to develop a novel injectable sustained release drug delivery system for a high value biological drug.

Read more about this story »

24 MAR 2011

The founders of luxury bag company Knomo share their thoughts on growing a brand

The founders of luxury bag company Knomo share their thoughts on growing a brand, why DJs need laptop bags and how Apple has kept them on their toes.

Read more about this story »

03 MAR 2011

PolyTherics new premises opened by Minister for Universities and Science, David Willetts

PolyTherics Ltd, an innovator in precision engineering of proteins to improve their pharmacokinetic properties, had its newly refurbished space at the London BioScience Innovation Centre (LBIC) opened on Tuesday 1st March by Rt Hon David Willetts, Minister of State for Universities and Science.

Read more about this story »

15 DEC 2010

Domainex wins Genesis Award for its work in supporting Translational Research

Domainex the leading UK-based drug discovery CRO, has won the 2010 Genesis Life Science Innovation and Enterprise Programme Of The Year Award. This Award was made in recognition of Domainex's proactive work on promoting academic-industry collaborations, and was adjudicated by leading representatives of the biotechnology and pharmaceutical industries.

Read more about this story »

Download press release (PDF) »

15 NOV 2010

Domainex collaborates with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology

Domainex, the Contract Research Organisation committed to excellence in drug discovery, today announced a collaboration with Sigma-Aldrich (Nasdaq: SIAL) that will provide tools, including biochemical assays and monoclonal antibodies, for the study of proteins involved in the rapidly developing field of epigenetics.

Download press release (PDF) »

The Capital Fund is managed by YFM Venture Finance Limited. YFM Venture Finance is authorised and regulated by the Financial Services Authority FRN: 224728 and is a wholly owned subsidiary of YFM Equity Partners Limited. YFM Equity Partners Limited is registered in England and Wales, Company No. 04848599. Registered Office: Saint Martins House, 210-212 Chapeltown Road, Leeds LS7 4HZ. YFM Equity Partners Limited is part of the GLE Group of companies. Trading names used in the past by the London office of YFM Venture Finance Limited include London Fund Managers, Yorkshire Venture Finance and Yorkshire Fund Managers.